Cargando…

Validation of the Chinese drug hypersensitivity quality of life questionnaire: Role of delabeling

The Drug Hypersensitivity Quality of Life Questionnaire (DrHy-Q) is not currently available in Chinese. Besides, penicillin allergy (PA) is a worldwide public health challenge, and delabeling inauthentic PA can improve clinical and economic outcomes. However, its effect on health-related quality of...

Descripción completa

Detalles Bibliográficos
Autores principales: Mak, Hugo W.F., Chan, Elsie T.S., Yim, Jackie S.H., Lee, Elaine, Lam, Dorothy L.Y., Chiang, Valerie, Li, Philip H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166238/
https://www.ncbi.nlm.nih.gov/pubmed/37389094
http://dx.doi.org/10.5415/apallergy.0000000000000020
_version_ 1785038402575400960
author Mak, Hugo W.F.
Chan, Elsie T.S.
Yim, Jackie S.H.
Lee, Elaine
Lam, Dorothy L.Y.
Chiang, Valerie
Li, Philip H.
author_facet Mak, Hugo W.F.
Chan, Elsie T.S.
Yim, Jackie S.H.
Lee, Elaine
Lam, Dorothy L.Y.
Chiang, Valerie
Li, Philip H.
author_sort Mak, Hugo W.F.
collection PubMed
description The Drug Hypersensitivity Quality of Life Questionnaire (DrHy-Q) is not currently available in Chinese. Besides, penicillin allergy (PA) is a worldwide public health challenge, and delabeling inauthentic PA can improve clinical and economic outcomes. However, its effect on health-related quality of life (HRQoL) remains poorly known. OBJECTIVE: The study objective is to translate and validate a Chinese version of DrHy-Q and investigate the effect of PA delabeling on HRQoL using DrHy-Q. METHODS: A Chinese DrHy-Q was translated then completed by patients with drug allergy labels for psychometric validation. Afterwards, another cohort of patients finished the Chinese DrHy-Q before and after their PA workup for pre–post comparison. RESULTS: A total of 130 patients were studied. Sixty-three patients (79.4% female; median age = 59 ± 15 years) completed the Chinese DrHy-Q for validation (mean score = 38.9 ± 23.5). It demonstrated excellent internal consistency (Cronbach α = 0.956; 95% confidence interval [CI], 0.939–0.971) and test–retest reliability (intraclass correlation coefficient = 0.993 [95% CI, 0.969–0.998]). Construct validity was confirmed by its one-dimensional structure in factor analysis. Divergent validity was established because only 2 (out of 9) SF-36 scales showed weak negative correlations to DrHy-Q. Patients with multiple implicated drugs presented significantly higher DrHy-Q scores than those with only a single drug (42.0 ± 22.5 vs 28.7 ± 24.4; P = 0.038), showing discriminant validity. Subsequently, another 67 patients (73.1% female; median age = 56 ± 15 years) underwent PA investigations and completed their pre–post DrHy-Q. A significant drop in DrHy-Q score was shown (40.8 ± 21.7 vs 26.6 ± 22.5; Cohen’s d = 0.964; P < 0.001), reflecting improvement in HRQoL. CONCLUSION: The Chinese DrHy-Q is reliable and valid for HRQoL assessment. PA delabeling significantly benefits patients’ HRQoL. Future larger-scale studies are warranted to corroborate our findings.
format Online
Article
Text
id pubmed-10166238
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-101662382023-06-29 Validation of the Chinese drug hypersensitivity quality of life questionnaire: Role of delabeling Mak, Hugo W.F. Chan, Elsie T.S. Yim, Jackie S.H. Lee, Elaine Lam, Dorothy L.Y. Chiang, Valerie Li, Philip H. Asia Pac Allergy Original Article The Drug Hypersensitivity Quality of Life Questionnaire (DrHy-Q) is not currently available in Chinese. Besides, penicillin allergy (PA) is a worldwide public health challenge, and delabeling inauthentic PA can improve clinical and economic outcomes. However, its effect on health-related quality of life (HRQoL) remains poorly known. OBJECTIVE: The study objective is to translate and validate a Chinese version of DrHy-Q and investigate the effect of PA delabeling on HRQoL using DrHy-Q. METHODS: A Chinese DrHy-Q was translated then completed by patients with drug allergy labels for psychometric validation. Afterwards, another cohort of patients finished the Chinese DrHy-Q before and after their PA workup for pre–post comparison. RESULTS: A total of 130 patients were studied. Sixty-three patients (79.4% female; median age = 59 ± 15 years) completed the Chinese DrHy-Q for validation (mean score = 38.9 ± 23.5). It demonstrated excellent internal consistency (Cronbach α = 0.956; 95% confidence interval [CI], 0.939–0.971) and test–retest reliability (intraclass correlation coefficient = 0.993 [95% CI, 0.969–0.998]). Construct validity was confirmed by its one-dimensional structure in factor analysis. Divergent validity was established because only 2 (out of 9) SF-36 scales showed weak negative correlations to DrHy-Q. Patients with multiple implicated drugs presented significantly higher DrHy-Q scores than those with only a single drug (42.0 ± 22.5 vs 28.7 ± 24.4; P = 0.038), showing discriminant validity. Subsequently, another 67 patients (73.1% female; median age = 56 ± 15 years) underwent PA investigations and completed their pre–post DrHy-Q. A significant drop in DrHy-Q score was shown (40.8 ± 21.7 vs 26.6 ± 22.5; Cohen’s d = 0.964; P < 0.001), reflecting improvement in HRQoL. CONCLUSION: The Chinese DrHy-Q is reliable and valid for HRQoL assessment. PA delabeling significantly benefits patients’ HRQoL. Future larger-scale studies are warranted to corroborate our findings. Lippincott Williams & Wilkins 2023-04-28 2023-03 /pmc/articles/PMC10166238/ /pubmed/37389094 http://dx.doi.org/10.5415/apallergy.0000000000000020 Text en Copyright © 2023. Asia Pacific Association of Allergy, Asthma and Clinical Immunology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Original Article
Mak, Hugo W.F.
Chan, Elsie T.S.
Yim, Jackie S.H.
Lee, Elaine
Lam, Dorothy L.Y.
Chiang, Valerie
Li, Philip H.
Validation of the Chinese drug hypersensitivity quality of life questionnaire: Role of delabeling
title Validation of the Chinese drug hypersensitivity quality of life questionnaire: Role of delabeling
title_full Validation of the Chinese drug hypersensitivity quality of life questionnaire: Role of delabeling
title_fullStr Validation of the Chinese drug hypersensitivity quality of life questionnaire: Role of delabeling
title_full_unstemmed Validation of the Chinese drug hypersensitivity quality of life questionnaire: Role of delabeling
title_short Validation of the Chinese drug hypersensitivity quality of life questionnaire: Role of delabeling
title_sort validation of the chinese drug hypersensitivity quality of life questionnaire: role of delabeling
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166238/
https://www.ncbi.nlm.nih.gov/pubmed/37389094
http://dx.doi.org/10.5415/apallergy.0000000000000020
work_keys_str_mv AT makhugowf validationofthechinesedrughypersensitivityqualityoflifequestionnaireroleofdelabeling
AT chanelsiets validationofthechinesedrughypersensitivityqualityoflifequestionnaireroleofdelabeling
AT yimjackiesh validationofthechinesedrughypersensitivityqualityoflifequestionnaireroleofdelabeling
AT leeelaine validationofthechinesedrughypersensitivityqualityoflifequestionnaireroleofdelabeling
AT lamdorothyly validationofthechinesedrughypersensitivityqualityoflifequestionnaireroleofdelabeling
AT chiangvalerie validationofthechinesedrughypersensitivityqualityoflifequestionnaireroleofdelabeling
AT liphiliph validationofthechinesedrughypersensitivityqualityoflifequestionnaireroleofdelabeling